Low SHBG Symptoms: Drugs That Cause or Treat It

What SHBG Does and Why Low Levels Matter

SHBG is a glycoprotein made primarily in the liver that binds testosterone, dihydrotestosterone (DHT), and estradiol with high affinity. It acts as the body's hormonal buffer, controlling how much free (unbound) hormone reaches androgen and estrogen receptors in target tissues [1]. Only 1 to 3% of circulating testosterone is free; SHBG binds roughly 40 to 60%, and albumin loosely binds the rest.

When SHBG falls below the reference range (approximately 20 to 130 nmol/L in adults, though lab-specific cutoffs vary), the fraction of bioavailable testosterone rises disproportionately. A person whose total testosterone reads "normal" can still experience androgen excess if SHBG is suppressed. This is why measuring SHBG alongside total testosterone gives clinicians a far more accurate picture of the hormonal environment than total testosterone alone [2].

Low SHBG is not simply a lab curiosity. A prospective analysis published in the New England Journal of Medicine (N=2,699 women, 3,156 men) demonstrated that each standard-deviation decrease in SHBG was associated with a relative risk of 1.28 for incident type 2 diabetes in men and 1.17 in women, independent of BMI and waist circumference [3]. The protein has since been recognized as both a biomarker and a possible causal factor in cardiometabolic disease.

Recognizing the Symptoms of Low SHBG

The symptom profile of low SHBG is driven by the downstream excess of free androgens (and, to a lesser extent, free estrogens). Symptoms differ between sexes, but metabolic overlap is significant.

In women, low SHBG frequently presents as acne concentrated along the jawline and chin, hirsutism (coarse terminal hair on the face, chest, or abdomen), androgenic alopecia with frontal thinning, and menstrual irregularity. These signs overlap heavily with polycystic ovary syndrome (PCOS), a condition in which low SHBG is both a diagnostic clue and a driver of hyperandrogenism [4]. The 2023 international evidence-based PCOS guideline explicitly recommends measuring SHBG when calculated free testosterone is needed for diagnosis.

In men, the picture is subtler. Paradoxically, men with very low SHBG may report fatigue and low libido despite "normal" total testosterone, because rapid clearance of unbound hormone can cause tissue-level fluctuations. Others experience oily skin, body acne, or accelerated male-pattern baldness [5].

In both sexes, metabolic symptoms predominate when SHBG suppression is chronic. These include central adiposity, fasting hyperglycemia, dyslipidemia with elevated triglycerides, and hepatic steatosis. A 2012 meta-analysis of 36 cross-sectional studies confirmed that SHBG is inversely associated with metabolic syndrome prevalence, with an odds ratio of 0.32 (95% CI 0.21 to 0.48) per log-unit increase in SHBG [6].

Why SHBG Drops: The Insulin Connection

Hyperinsulinemia is the single most potent physiological suppressor of hepatic SHBG production. Insulin directly inhibits SHBG gene transcription in hepatocytes through a mechanism involving hepatocyte nuclear factor 4-alpha (HNF-4α) [7]. This creates a vicious feedback loop: insulin resistance lowers SHBG, which raises free androgens, which promote visceral fat deposition, which worsens insulin resistance.

Conditions tied to insulin resistance consistently show low SHBG. Type 2 diabetes, PCOS, non-alcoholic fatty liver disease (now termed metabolic dysfunction-associated steatotic liver disease, or MASLD), and obesity with central adiposity all correlate with SHBG levels in the bottom quartile of the population distribution [3][7]. Hypothyroidism also lowers SHBG by reducing hepatic protein synthesis broadly, though the effect is modest compared to hyperinsulinemia [8].

Cortisol excess (endogenous Cushing syndrome or prolonged exogenous glucocorticoid use) suppresses SHBG as well, likely through a combination of direct hepatic effects and secondary insulin resistance [9].

Drugs That Lower SHBG

Several medication classes suppress SHBG production or binding capacity. Recognizing these drug-induced drops prevents misdiagnosis of an endocrine disorder when the real cause is pharmacologic.

Exogenous androgens. Testosterone replacement therapy (TRT) in any formulation (injections, gels, pellets, oral testosterone undecanoate) lowers SHBG, typically by 20 to 50% within the first 3 to 6 months of use. The 2018 Endocrine Society guideline on testosterone therapy in men with hypogonadism notes this expected SHBG decline and recommends monitoring free testosterone (calculated via SHBG) rather than relying on total testosterone alone during TRT [5]. Supraphysiologic androgen doses used in bodybuilding can suppress SHBG to single-digit values. Danazol, a synthetic androgen used for endometriosis, produces dose-dependent SHBG reductions of 40 to 80% [10].

Insulin and insulin sensitizers. Exogenous insulin therapy in type 2 diabetes compounds the SHBG-lowering effect of endogenous hyperinsulinemia. Each additional 10 units of daily insulin has been associated with a measurable further decline in SHBG in observational data [7]. The effect of metformin is more nuanced and discussed in the treatment section below.

Certain progestins. Androgenic progestins (levonorgestrel, norethindrone, norgestrel) lower SHBG by 15 to 30% when used in hormonal contraceptives or menopausal hormone therapy. The levonorgestrel-releasing intrauterine system (Mirena) has minimal systemic effect on SHBG due to low circulating progestin levels, but combined oral pills containing levonorgestrel consistently reduce SHBG compared to pills with anti-androgenic progestins like drospirenone [11].

Glucocorticoids. Chronic use of prednisone, dexamethasone, or other systemic corticosteroids suppresses SHBG through hepatic and metabolic pathways. The magnitude depends on dose and duration; short courses (<2 weeks) have negligible impact, but chronic therapy at doses equivalent to prednisone 7.5 mg/day or higher often produces clinically meaningful reductions [9].

Growth hormone (GH). GH replacement therapy in adults with GH deficiency lowers SHBG by approximately 15 to 25%, an effect attributed to GH's insulin-antagonistic actions at the liver [12].

Drugs That Raise SHBG

When low SHBG is causing clinical symptoms (particularly androgen-excess symptoms in women or metabolic risk in either sex), pharmacologic SHBG elevation can be a direct therapeutic target or a beneficial side effect.

Oral estrogens. Ethinyl estradiol (the estrogen in most combined oral contraceptive pills) is the most potent pharmaceutical SHBG elevator. First-pass hepatic metabolism of oral estrogen stimulates SHBG gene expression, producing 2 to 4-fold increases in circulating SHBG [11]. This mechanism is a primary reason combined oral contraceptives improve acne and hirsutism in women with PCOS. Pills containing anti-androgenic progestins (drospirenone, cyproterone acetate, chlormadinone) raise SHBG even more than those with androgenic progestins, because they avoid the opposing SHBG-suppressive effect of androgenic progestins. A 2014 Cochrane review of oral contraceptives for hirsutism confirmed SHBG increases across all formulations, with the greatest magnitude seen with ethinyl estradiol/cyproterone acetate combinations [13]. Transdermal estrogen, by contrast, bypasses first-pass hepatic metabolism and raises SHBG only modestly (10 to 20%).

Tamoxifen and raloxifene. Selective estrogen receptor modulators (SERMs) act as estrogen agonists in the liver and raise SHBG by 50 to 100% at standard oncologic doses (tamoxifen 20 mg/day). In men receiving tamoxifen off-label for gynecomastia or hypogonadism, the SHBG increase must be accounted for when interpreting total testosterone values, because total T rises partly from SHBG binding rather than increased production [14].

Levothyroxine. In patients with hypothyroidism, restoring euthyroid status with levothyroxine normalizes SHBG. Thyroid hormone is a direct transcriptional activator of SHBG gene expression. The correction is proportional to the severity of hypothyroidism; patients with TSH above 10 mIU/L at baseline typically see SHBG increase by 30 to 60% after dose optimization [8].

Thiazolidinediones. Pioglitazone, a PPARγ agonist used in type 2 diabetes, raises SHBG by 15 to 30% in most studies, likely through reduction of hyperinsulinemia and improvement of hepatic insulin sensitivity rather than a direct hepatic effect [15]. This dual benefit (glycemic control plus SHBG restoration) makes pioglitazone a consideration in patients with both metabolic syndrome and androgen-excess symptoms, though fluid retention and fracture risk limit its use.

Metformin. Data on metformin's effect on SHBG are mixed. Some studies in women with PCOS show a 10 to 20% increase in SHBG after 3 to 6 months of metformin 1,500 to 2,000 mg/day, driven by reduced insulin levels [16]. Other trials show no significant change. The 2023 international PCOS guideline lists metformin as a second-line option for metabolic features of PCOS but does not endorse it specifically as an SHBG-raising agent [4].

Statins. HMG-CoA reductase inhibitors produce a modest (5 to 15%) increase in SHBG in some observational studies, potentially through altered hepatic cholesterol metabolism. The clinical significance of this effect is unclear, and no guideline recommends statin therapy for SHBG modification [17].

Diagnostic Workup for Low SHBG

A single low SHBG value requires context. The standard approach is a fasting morning blood draw measuring SHBG alongside total testosterone, albumin, fasting insulin, fasting glucose or HbA1c, liver function tests (ALT, AST), TSH, and a lipid panel [2][5].

Free testosterone should be calculated using the Vermeulen equation (which requires SHBG, total testosterone, and albumin) rather than measured by direct analog immunoassay, which is unreliable at both extremes of SHBG [5]. The Endocrine Society's 2018 guideline explicitly discourages direct free testosterone assays and recommends calculated free T or equilibrium dialysis as the reference methods.

Low SHBG in isolation (no symptoms, no metabolic abnormalities) rarely warrants treatment. When symptoms of androgen excess or metabolic dysfunction are present, the workup expands to include pelvic ultrasound in women (to assess for polycystic ovarian morphology), DHEA-S, 17-hydroxyprogesterone (to rule out non-classic congenital adrenal hyperplasia), and prolactin [4].

Repeat testing at 6 to 12 weeks after initiating any SHBG-modifying drug confirms whether the intervention is working. SHBG has a circulating half-life of approximately 7 days, so steady-state changes in hepatic production take several weeks to fully manifest in serum levels.

Treatment Strategy: Matching the Intervention to the Cause

The most effective treatment for low SHBG is treating the condition or removing the drug that caused it. A 2019 systematic review of lifestyle interventions in PCOS found that 5 to 10% weight loss raised SHBG by a mean of 23% (95% CI 14 to 32%) across 12 trials [18]. Caloric restriction and aerobic exercise both reduce insulin levels, which removes the primary brake on hepatic SHBG production.

For drug-induced SHBG suppression, the approach depends on clinical priority. A man on TRT whose SHBG has dropped to 8 nmol/L may need dose reduction or a switch from intramuscular injections (which produce supraphysiologic peaks) to transdermal testosterone (which creates more stable levels and less SHBG suppression). A woman experiencing acne on a levonorgestrel-containing oral contraceptive may benefit from switching to a drospirenone-containing pill, which raises rather than lowers SHBG [11].

When the underlying cause cannot be removed (for example, type 2 diabetes requiring insulin therapy), targeted pharmacologic SHBG elevation becomes the strategy. The clinical decision matrix typically follows this sequence:

1. Address insulin resistance first. Weight loss, metformin, or pioglitazone.
2. Correct hypothyroidism if TSH is elevated.
3. Consider oral estrogen therapy in premenopausal women with androgen-excess symptoms.
4. Reassess in 12 weeks with repeat SHBG and calculated free testosterone.

Dr. Richard Auchus, Professor of Internal Medicine at the University of Michigan, has noted: "SHBG is one of the most underappreciated lab values in endocrinology. A total testosterone in the normal range means very little if you don't know the SHBG."

The Endocrine Society's clinical practice guideline on androgen excess and PCOS in women states: "We recommend using calculated free testosterone or the free androgen index for the biochemical diagnosis of hyperandrogenism, particularly when total testosterone levels are normal" [4].

When Low SHBG Signals Something Serious

Most cases of low SHBG trace back to insulin resistance, obesity, or medications. Occasionally, a very low SHBG (<10 nmol/L) in a lean, otherwise healthy individual raises concern for rarer diagnoses: androgen-secreting tumors (ovarian or adrenal), Cushing syndrome, or acromegaly. A rapid onset of virilization in a woman with suppressed SHBG and markedly elevated testosterone (>200 ng/dL) warrants urgent imaging and endocrine referral [4].

Genetic polymorphisms in the SHBG gene (rs1799941, among others) can also produce constitutively low SHBG levels that are clinically benign. These individuals have lifelong low SHBG without metabolic consequences, though population studies suggest even genetically determined low SHBG may confer modest long-term cardiometabolic risk [3].

Hepatic cirrhosis can either raise or lower SHBG depending on the degree of estrogenization versus synthetic failure. Advanced liver disease with severe synthetic dysfunction drops SHBG, along with albumin and other hepatic proteins.

The practical threshold for clinical concern: SHBG below 20 nmol/L in a woman or below 15 nmol/L in a man, combined with symptoms of androgen excess or metabolic dysfunction, warrants full endocrine workup and intervention. An SHBG of 18 nmol/L in an asymptomatic patient with BMI 34 and known insulin resistance typically requires metabolic treatment rather than isolated SHBG correction.